2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
653 Views
2019 Hong Kong IPO Analytics: Highlight of Brokers’ and Sectors’ Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
793 Views
Hansoh Pharma's Lock-Up Expiry: Valuation and the Trade
Lock-up restriction for Hansoh Pharma's controlling shareholder, pre-IPO investors and cornerstone investors will expire on December 14th. We...
596 Views
Hansoh Pharma's Lock-Up Expiry - New Drugs Offset the Impact of Centralized Procurement
Lock-up restriction for Hansoh Pharma's controlling shareholder, pre-IPO investors and cornerstone investors will expire on December 14th. As we...
563 Views
Hansoh Pharma's HS-10296 - How Far Is It From Billion $ Tagrisso? Our Read on Phase 2 Reports
Hansoh Pharma, a leading China-based pharmaceutical company, recorded a stellar post-IPO performance since its listing in June. As a big portion of...
568 Views